Patents by Inventor Nicholas B. La Thangue
Nicholas B. La Thangue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10012652Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: GrantFiled: April 29, 2016Date of Patent: July 3, 2018Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Nicholas B. La Thangue, Susan Fotheringham
-
Publication number: 20170219594Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: ApplicationFiled: April 29, 2016Publication date: August 3, 2017Inventors: Nicholas B. La Thangue, Susan Fotheringham
-
Patent number: 9347103Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: GrantFiled: June 16, 2014Date of Patent: May 24, 2016Assignee: ISIS Innovation LimitedInventors: Nicholas B. La Thangue, Susan Fotheringham
-
Publication number: 20160069887Abstract: The invention relates to biomarkers for determining the prognosis of cancer patients. By determining the level of the biomarker HR23B in the cell or patient, and optionally determining the levels of one or more of the biomarkers HDAC6, LC3 and HSP90, the invention provides a method for determining the susceptibility of a cell or a patient of interest to entering an autophagocytic state upon treatment with a drug. The invention also provides a method of determining susceptibility of a cell or patient to treatment with a drug. Entering an autophagocytic state is thought to be a tumour cell survival mechanism, whereby the tumour cell avoids apoptosis. The methods of the invention may therefore be helpful for determining whether a patient should be treated and for determining the prognosis upon drug treatment.Type: ApplicationFiled: April 8, 2014Publication date: March 10, 2016Inventor: Nicholas B. La Thangue
-
Publication number: 20140369999Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: ApplicationFiled: June 16, 2014Publication date: December 18, 2014Inventors: Nicholas B. La Thangue, Susan Fotheringham
-
Patent number: 8784806Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: GrantFiled: March 27, 2007Date of Patent: July 22, 2014Assignee: Isis Innovation LimitedInventors: Nicholas B. La Thangue, Susan Fotheringham
-
Publication number: 20090311244Abstract: This invention relates to a novel screening method that identifies simple molecular markers that are predictive of whether a particular disease condition is responsive to a specific treatment. Also, a method of diagnosing the susceptibility of an individual suffering from a disease to treatment with an HDAC inhibitor is provided. Also provided is a method of treating a proliferative disease or a condition which involves a change in cell differentiation or growth rate in a patient.Type: ApplicationFiled: March 27, 2007Publication date: December 17, 2009Applicant: ISIS INNOVATION LIMITEDInventors: Nicholas B. La Thangue, Susan Fotheringham
-
Patent number: 7160981Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonizing the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.Type: GrantFiled: July 9, 2001Date of Patent: January 9, 2007Assignee: Prolifix LimitedInventors: Nicholas B. La Thangue, Lasantha R. Bandara
-
Publication number: 20030022260Abstract: Two novel transcription factors belonging to the E2F gene family, are disclosed. These are human and murine E2F-5. They can interact with DP-1 and p130.Type: ApplicationFiled: August 8, 2002Publication date: January 30, 2003Applicant: PROLIFIX LIMITEDInventors: Nicholas B. La Thangue, Rene Bernards, Eleanore M. Hijmans
-
Patent number: 6448376Abstract: Two novel transcription factors belonging to the E2F gene family, are disclosed. These are human and murine E2F-5. They can interact with DP-1 and p130.Type: GrantFiled: August 13, 1997Date of Patent: September 10, 2002Assignee: Prolifix LimitedInventors: Nicholas B. La Thangue, Rene Bernards, Eleonore M. Hijmans
-
Publication number: 20020103121Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonizing the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.Type: ApplicationFiled: July 9, 2001Publication date: August 1, 2002Applicant: Prolifix LimitedInventors: Nicholas B. La Thangue, Lasantha R. Bandara
-
Patent number: 6387649Abstract: The present invention provides nuclear localisation signals derived from the DP-3 and E2F-1 transcription factors and the use of these signals in assays for regulators of cell cycle progression. Such assays involve using the signals to direct a marker gene to the nucleus and determining whether the nuclear localisation of the marker is disrupted by the presence of a putative regulator.Type: GrantFiled: November 14, 2000Date of Patent: May 14, 2002Assignee: Prolifix LimitedInventors: Nicholas B. La Thangue, Susana De La Luna
-
Patent number: 6268334Abstract: The invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1 as shown in the Figure, and fragments and variants thereof capable of antagonising the heterodimerization of a DP protein with an E2F protein. Such peptides may be used to induce apoptosis in a cell by introducing into the cell an effective amount of said peptide. Such cells include cardiovascular cells, and the peptide may be delivered in a stent to treat or prevent restinosis.Type: GrantFiled: May 27, 1999Date of Patent: July 31, 2001Assignee: Prolifix LimitedInventors: Nicholas B. La Thangue, Lasantha R. Bandara
-
Patent number: 5859199Abstract: The invention provides polypeptides of transcription factor DP-3 which exists in four isoforms produced by alternative splicing of mRNA, nucleic acid encoding the polypeptides and the use of such nucleic acid and polypeptides in assays. Two isoforms of DP-3 contain a region, designated the E region, which is a nuclear localization signal and is involved in a further level of regulation of DP-3 and its ability to bind to E2F-1 and regulate the cell cycle.Type: GrantFiled: September 30, 1996Date of Patent: January 12, 1999Assignee: Prolifix LimitedInventors: Nicholas B. La Thangue, Susana de la Luna